Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1469-1476

  Takaoka, Sayaka ^a   Iwase, Masayasu ^a   Uchida, Makiko ^a   Yoshiba, Sayaka ^a   Kondo, Gen ^a   Watanabe, Hitoshi ^a   Ohashi, Masaru ^a   Nagumo, Masao ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Apoptosis; Cisplatin; Epidermal growth factor receptor inhibitor; Oral squamous cell carcinoma; Proliferation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENZYME INHIBITORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MOUTH NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 34447283545     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1469     Document Type: Article

References (61)

1. Forastiere AA, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
2. Jefferies S and Foulkes WD: Genetic mechanisms in squamous cell carcinoma. Oral Oncol 37: 115-126, 2001.
3. Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
4. De Andres L, Brunet J, Lopez-Pousa A, et al: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13: 1493-1500, 1995.
5. Bourhis J: New approaches to enhance chemotherapy in SCCHN. Ann Oncol 16: 20-24, 2005.
6. Gonzalez VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001.
7. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell 2: 275-280, 1990.
8. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
9. Hersey P and Zhang XD: Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 196: 9-18, 2003. (Pubitemid 36676439)
10. Kaufmann SH and Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22: 7414-7430, 2003.
11. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20: S1-S13, 2002.
12. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29: S3-S9, 2002.
13. Shin DM, Ro JY, Hong WK and Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994.
14. Rubin Grandis J, Melhem MF, Barnes EL and Tweardy DJ: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284-1292, 1996.
15. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N and Kitajima M: Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2: 909-914, 1996. (Pubitemid 26168944)
16. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
17. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
18. Herbst RS and Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611, 2002.
19. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987, 2003.
20. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS and Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85, 2004.
21. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000.
22. Bianco C, Tortora G, Bianco R, et al: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3250-3258, 2002.
23. Magne N, Fischel JL, Tiffon C, et al: Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89: 585-592, 2003.
24. Herbst RS, Arquette M, Shin DM, et al: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578-5587, 2005.
25. Pfister DG, Su YB, Kraus DH, et al: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078, 2006.
26. Watanabe H, Iwase M, Ohashi M and Nagumo M: Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38: 670-679, 2002. (Pubitemid 34880105)
27. Iwase M, Watanabe H, Kondo G, Ohashi M and Nagumo M: Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 106: 619-625, 2003.
28. Kondo G, Iwase M, Watanabe H, et al: Enhancement of susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells by phosphatidylinositol 3-kinase inhibitor. Oral Oncol 42: 745-752, 2006.
29. Bancroft CC, Chen Z, Yeh J, et al: Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and Ap-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002.
30. Datta SR, Dudek H, Tao X, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
31. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
32. Huang S, Armstrong EA, Benavente S, Chinnaiyan P and Harari PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64: 5355-5362, 2004.
33. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002.
34. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathway. Clin Cancer Res 9: 2316-2326, 2003.
35. Salvesen GS and Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401-410, 2002.
36. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002. (Pubitemid 37328916)
37. Kojima H, Endo K, Moriyama H, et al: Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 273: 16647-16650, 1998.
38. Kuwahara D, Tsutsumi K, Kobayashi T, Hasunuma T and Nishioka K: Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Lett 148: 65-71, 2000.
39. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541-546, 1995.
40. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-110, 1999.
41. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS and Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10: 1359-1366, 2000.
42. Kasof GM and Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276: 3238-3246, 2001. (Pubitemid 37411617)
43. Noutomi T, Chiba H, Itoh M, Toyota H and Mizuguchi J: Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncol 38: 41-48, 2002.
44. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002.
45. Hu Y, Cherton-Horvat G, Dragowska V, et al: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836, 2003.
46. Schimmer AD, Welsh K, Pinilla C, et al: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5: 25-35, 2004.
47. Kurebayashi J, Okubo S, Yamamoto Y, et al: Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 58: 460-470, 2006. (Pubitemid 43999794)
48. Ariyama H, Qin B, Baba E, et al: Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97: 724-734, 2006.
49. Liu Z, Li H, Derouet M, et al: ras oncogene triggers upregulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem 280: 37383-37392, 2005.
50. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L: Cross-talk between epidermal growth factor receptor and HIF-1α signal pathways increases resistance to apoptosis by upregulating survivin gene expression. J Biol Chem 281: 25903-25914, 2006.
51. Peng XH, Cao ZH, Xia JT, et al: Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 65: 1909-1917, 2005.
52. Asanuma H, Torigoe T, Kamiguchi K, et al: Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65: 11018-11025, 2005.
53. Gilmore AP, Valentijn AJ, Wang P, et al: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277: 27643-27650, 2002.
54. Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994, 2000.
55. Chen X, Thakkar H, Tyan F, et al: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083, 2001.
56. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774, 2001. (Pubitemid 38089250)
57. Sharma H, Sen S and Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4: 949-955, 2005.
58. Vianco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
59. Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003.
60. Campos L, Sabido O, Rouault JP and Guyotat D: Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84: 595-600, 1994.
61. Li J, Feng Q, Kim JM, et al: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380, 2001.